Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from RedHill Biopharma

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap: Redhill Biopharma Q1 Earnings

Redhill Biopharma (NASDAQ:RDHL) reported its Q1 earnings results on Thursday, June 23, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Redhill Biopharma reported an EPS of $0.03.

Redhill Biopharma's Earnings: A Preview

Redhill Biopharma (NASDAQ:RDHL) is set to give its latest quarterly earnings report on Thursday, 2022-06-23. Here's what investors need to know before the announcement. Analysts estimate that Redhill Biopharma will report an earnings per share (EPS) of $-0.23.

12 Health Care Stocks Moving In Monday's Intraday Session

RedHill, Kukbo Ink Oral Opaganib Licensing Pact For COVID-19 In South Korea

RedHill Biopharma Ltd (NASDAQ:RDHL) has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea. Under the terms of the license agreement, which follows the previously announced strategic investment by Kukbo, RedHill will receive an upfront payment of $1.5 million. Redhill is eligible for up to $5.6 million…

inkl

Read news from The Economist, FT, and more,
with one subscription

RedHill Biopharma's Upamostat Shows 100% Efficacy In Non-Hospitalized COVID-19 Patients

RedHill Biopharma's Upamostat Shows 100% Efficacy In Non-Hospitalized COVID-19 Patients

RedHill Biopharma Ltd (NASDAQ: RDHL) has

RedHill Biopharma's COVID-19 Antiviral Cuts Mortality By 70% In Remdesivir Treated Patients

RedHill Biopharma's COVID-19 Antiviral Cuts Mortality By 70% In Remdesivir Treated Patients

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced results from two recently completed prespecified analyses from the oral opaganib Phase 2/3 study in hospitalized severe COVID-19.

Organisations

European Commission

Blueprint Medicines

Sunshine Biopharma

Quoin Pharmaceuticals

Great Elm Group

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play